No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 0.5x · 10Y median 1.2x · 13th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 18
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:55:45.260Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T11:55:45.260Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T11:55:45.260Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T11:55:45.260Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T11:55:45.260Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T11:55:45.260Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T11:55:45.260Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T11:55:45.260Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Astrana Health, Inc. (ASTH) stock was $36.81 as of Oct 5, 2026, 4:00 PM EDT, up 2.59% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +27.9% · 3-year avg +4.5%/yr · 5-year avg -16.5%/yr
Astrana Health, Inc., which rebranded from Apollo Medical Holdings, Inc. in February 2024, is a healthcare management firm based in Alhambra, California, founded in 1985.
Medical - Care Facilities · Alhambra, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
0.45
Revenue Est.
$1.02B
Last Quarter Results
EPS
$0.80
vs Estimate
$0.73
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ASTH | $1.83B | $36.81 | +2.59% | +27.88% | -16.52% | +25.17% | N/A |
| 2AGIO | $1.87B | $31.25 | -1.73% | -22.74% | -6.59% | -5.39% | vs ASTH |
| 3NTLA | $1.78B | $12.75 | +4.00% | -35.99% | -37.13% | -3.03% | vs ASTH |
| 4BLFS | $1.89B | $38.61 | +3.51% | +44.95% | -0.77% | +36.27% | vs ASTH |
| 5ALHC | $1.76B | $8.50 | +7.05% | -48.69% | -12.15% | N/A | vs ASTH |
| 6XRAY | $1.71B | $8.56 | -1.27% | -34.07% | -30.27% | -16.38% | vs ASTH |
2.20
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$972.50M
vs Estimate
$982.23M
Consensus Rating
Based on 9 analysts
Average Price Target
$51.67
+40.4% upside
Low
$41.00
Current
$36.81
High
$65.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.41 | $0.45 | $0.51 | 3 |
| Quarter ending Dec 2026 | $0.23 | $0.26 | $0.29 | 3 |
| Quarter ending Mar 2027 | $0.44 | $0.45 | $0.47 | 1 |
| Quarter ending Jun 2027 | $0.49 | $0.50 | $0.52 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.35 | $1.40 | $1.49 | 5 |
| FY 2027 | $1.82 | $1.97 | $2.24 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.00B | $1.02B | $1.05B | 6 |
| Quarter ending Dec 2026 | $1.01B | $1.02B | $1.04B | 6 |
| Quarter ending Mar 2027 | $1.05B | $1.07B | $1.10B | 3 |
| Quarter ending Jun 2027 | $1.06B | $1.08B | $1.12B | 3 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $3.97B | $3.98B | $3.99B | 7 |
| FY 2027 | $4.22B | $4.38B | $4.57B | 8 |
